Brugada syndrome: Eligibility for subcutaneous implantable cardioverter-defibrillator after exercise stress test.
Brugada syndrome
Cardioversor-desfibrilhador implantável subcutâneo
Exercise stress test
Prova de esforço
Rastreio
Screening
Subcutaneous implantable cardioverter-defibrillator
Síndrome de Brugada
Journal
Revista portuguesa de cardiologia
ISSN: 2174-2049
Titre abrégé: Rev Port Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101770878
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
09
10
2019
revised:
25
03
2020
accepted:
05
05
2020
pubmed:
14
1
2021
medline:
1
9
2021
entrez:
13
1
2021
Statut:
ppublish
Résumé
Brugada syndrome (BrS) is a channelopathy associated with ventricular arrhythmias and sudden cardiac death. In patients at high risk of sudden death, an implantable cardioverter-defibrillator is indicated. Subcutaneous implantable cardioverter-defibrillators (S-ICDs) are an alternative to transvenous systems, with reduced risk of infection and complications associated with system extraction or explantation. To test electrocardiographic eligibility for S-ICD placement after exercise stress testing (EST) in patients with BrS. The sample included 35 consecutive patients with BrS. Electrocardiographic eligibility was assessed using the Boston Scientific model 2889 EMBLEM™ S-ICD automated screening tool, in four phases: decubitus and orthostatism, and before and after EST. Those who had at least one acceptable vector in the four measurements were considered eligible. In this study, 71.4% of patients were male and mean age was 53.86±12 years. In screening prior to EST, 14.3% of patients (n=5) were not eligible for an S-ICD. There was a statistically significant association between ineligibility and presence of complete right bundle branch block and history of syncope. After EST, 16.7% of initially eligible patients no longer had eligible vectors (n=5). In this study, 16.7% of patients previously eligible for an S-ICD were no longer eligible after EST. This result demonstrates the importance of screening after EST in all patients with BrS and with indication for an S-ICD, and may influence decisions concerning which ICD to implant or whether to institute pharmacological measures that avoid inappropriate therapies.
Identifiants
pubmed: 33436324
pii: S0870-2551(20)30447-9
doi: 10.1016/j.repc.2020.05.013
pii:
doi:
Types de publication
Journal Article
Langues
eng
por
Sous-ensembles de citation
IM
Pagination
33-38Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.